Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic
Parkinson's disease (PD). However, strategies aimed at ameliorating mitochondrial …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

Highly reproducible epidemiological evidence shows that type 2 diabetes (T2D) increases
the risk and rate of progression of Parkinson's disease (PD), and crucially, the repurposing …

Background A number of peptide incretin receptor agonists (IRAs) show promise as
therapeutics for Alzheimer's disease (AD) and Parkinson's disease (PD). Transport across …

Insulin desensitization has been observed in the brains of patients with Parkinson's disease
(PD), which is a progressive neurodegenerative disorder for which there is no cure …

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent
data highlight similarities between neurodegenerative diseases, including PD and type 2 …

Introduction Diabetes is a risk factor for Parkinson's disease (PD) and shares similar
dysregulated insulin pathways. Glucagon-like peptide-1 (GLP-1) analogs originally …

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are
peptide hormones and growth factors. A major pathological feature of both Alzheimer's dis …

Parkinson's disease (PD) is the second most common neurodegenerative disease, and no
treatment is available to stop its progression. Studies have shown that the colonic pathology …